Ginkgo Bioworks Holdings Second Quarter 2025 Earnings: Beats Expectations

August 09, 2025

Simply Wall St

NYSE:DNA 1 Year Share Price vs Fair Value

Explore Ginkgo Bioworks Holdings's Fair Values from the Community and select yours

Ginkgo Bioworks Holdings (NYSE:DNA) Second Quarter 2025 Results

Key Financial Results

Revenue: US$49.6m (down 12% from 2Q 2024).
Net loss: US$60.3m (loss narrowed by 72% from 2Q 2024).
US$1.10 loss per share (improved from US$4.23 loss in 2Q 2024).

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

earnings-and-revenue-growth — NYSE:DNA Earnings and Revenue Growth August 9th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Ginkgo Bioworks Holdings Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 19%. Earnings per share (EPS) also surpassed analyst estimates by 30%.

Looking ahead, revenue is expected to decline by 4.9% p.a. on average during the next 2 years, while revenues in the Life Sciences industry in the US are expected to grow by 5.9%.

Performance of the American Life Sciences industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 2 warning signs for Ginkgo Bioworks Holdings you should be aware of.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.